Novo Nordisk v. Paddock Laboratories, No. 12-1031 (Fed. Cir. June 18, 2013)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Novo Nordisk, Inc. and Novo Nordisk A/S (“Novo”) appeal from a judgment by the United States District Court for the District of Minnesota that claim 4 of its U.S. Patent No. 6,677,358 (“’358 patent”) is invalid as obvious and that the ’358 p atent is unenforceable due to inequit a- ble conduct. Novo Nordisk, Inc. v. Paddock Labs. , Inc. , 797 F. Supp. 2d 926, 935 (D. Minn. 2011) (“ No- vo/Paddock”). This case is a companion case to Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories, Ltd. , No. 2011-1223 (Fed. Cir.